Tamoxifen (Latest Articles)

Latest indexed articles for 'Tamoxifen'

Articles 1 to 10 of 200:

Genetic matters of CYP2D6 in breast cancer: copy number variations and nucleotide polymorphisms.

30 Oct 2009
rec_pub_19866496-genetic-matters-cyp2d6-breast-cancer-copy-number-variations.htm

EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.

30 Oct 2009 The tumor-specific, ligand-independent, constitutively active epidermal growth factor receptor (EGFR) variant, EGFRvIII, remains understudied in breast cancer. Here, we report that expression of EGFRvIII in the ErbB-2-overexpressing, ...
rec_pub_19588487-egfrviii-induced-estrogen-independence-tamoxifen-resistance-phenotype.htm

Gal4 turnover and transcription activation.

6 Oct 2009 Growing evidence supports the notion that proteasome-mediated destruction of transcriptional activators can be intimately coupled to their function. Recently, Nalley et al. challenged this view by reporting that the prototypical yeast activator Gal4 ...
rec_pub_19812621-gal4-turnover-transcription-activation.htm

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

5 Oct 2009 CONTEXT: The growth inhibitory effect of tamoxifen, which is used for the treatment of hormone receptor-positive breast cancer, is mediated by its metabolites, 4-hydroxytamoxifen and endoxifen. The formation of active metabolites is catalyzed by the ...
rec_pub_19809024-association-cyp2d6-polymorphisms-outcomes-women-early-stage-breast.htm

Tamoxifen, antidepressants, and CYP2D6: the conundrum continues.

29 Sep 2009
rec_pub_19797723-tamoxifen-antidepressants-cyp2d6-conundrum-continues.htm

Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy.

29 Sep 2009
rec_pub_19731103-pharmacology-pharmacogenetics-pharmacoepidemiology-three-ps.htm

American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

29 Sep 2009
rec_pub_19716939-american-society-clinical-oncology-clinical-practice-guideline-update.htm

Selective estrogen receptor modulators decrease reactive astrogliosis in the injured brain: effects of aging and prolonged depletion of ovarian hormones.

22 Sep 2009 After brain injury, astrocytes acquire a reactive phenotype characterized by a series of morphological and molecular modifications, including the expression of the cytoskeletal protein vimentin. Previous studies have shown that estradiol ...
rec_pub_19797123-selective-estrogen-receptor-modulators-decrease-reactive-astrogliosis.htm

Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene.

19 Sep 2009 PURPOSE: To compare the effects of two selective estrogen receptor modulators, tamoxifen and raloxifene, on global and domain-specific cognitive function. PATIENTS AND METHODS: The National Surgical Adjuvant Breast and Bowel Project's Study of ...
rec_pub_19770382-effects-tamoxifen-raloxifene-memory-cognitive-abilities-cognition.htm

TMEM25, REPS2 and Meis 1: favourable prognostic and predictive biomarkers for breast cancer.

19 Sep 2009 BACKGROUND/AIMS: A panel of prognostic and predictive biomarkers would contribute to personalized treatment of breast cancer patients. However, many such biomarkers have yet to be identified and evaluated. The aim of this study was to investigate ...
rec_pub_19776672-tmem25-reps2-meis-1-favourable-prognostic-predictive-biomarkers.htm

Results: [1-10] [11-20] [21-30] [31-40] [41-50] [51-60] [61-70] [71-80] [81-90] [91-100] [101-110] [111-120] [121-130] [131-140] [141-150] [151-160] [161-170] [171-180] [181-190] [191-200]